Loading...
XSHE
301111
, Last price  
Name

Guangdong Lifestrong Pharmacy Co Ltd

Chart & performance

D1W1MN
XSHE:301111 chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
6.08%
Rev. 5Y
-2.30%
Div Yld LY
—
Div Yld TTM
—
Revenues
311m
+11.74%
191,588,866290,494,774316,584,990340,956,597349,788,913349,788,913283,336,348283,336,347292,397,131278,638,789311,358,846
Net income
-4m
L
32,757,45763,600,42866,633,12062,521,67257,181,85657,181,86033,419,21433,419,21733,501,7004,162,686-4,488,758
CFO
20m
+524.51%
7,043,42341,397,06948,702,94790,904,19671,626,61269,879,889-12,799,2273,208,54320,037,817
Dividend
Jun 11, 20260.05 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangdong Lifestrong Pharmacy Co., Ltd. is a pharmaceutical company primarily involved in the research, development, manufacturing, and sales of various medical products. Its extensive product range includes different dosage forms such as tablets, pills, injections, mixtures, and granules. The company's therapeutic areas of focus encompass respiratory conditions, pediatric care, gynecology, urinary tract health, and nutritional and general healthcare solutions. This enterprise was established in 1951 and operates out of Shantou, China.
IPO date
Dec 07, 2021
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT